Patrick Grierson
YOU?
Author Swipe
View article: 585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity Open
View article: Supplementary Table 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Supplementary Table 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Supplementary Table 1. Antibodies used in flow cytometry.
View article: Data from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Data from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Purpose:Targeting tumor-associated macrophages through C–C chemokine receptor type 2 (CCR) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T-cell immunity in preclinical models.Patients and Met…
View article: Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Supplementary Table 2. Representativeness of study participants.
View article: Supplementary Figure 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Supplementary Figure 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Supplementary Figure 1. Data supporting correlative analyses.
View article: Eccrine carcinomas and homologous recombination repair cancer predisposition genes: A case series
Eccrine carcinomas and homologous recombination repair cancer predisposition genes: A case series Open
View article: Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer Open
Purpose: Targeting tumor-associated macrophages through C–C chemokine receptor type 2 (CCR) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T-cell immunity in preclinical models. Patients and M…
View article: 588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH Open
View article: 589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials
589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials Open
View article: The TRIM4 E3 ubiquitin ligase degrades TPL2 and is modulated by oncogenic KRAS
The TRIM4 E3 ubiquitin ligase degrades TPL2 and is modulated by oncogenic KRAS Open
View article: Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer Open
Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy. Ut…
View article: Data from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Data from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy Open
Purpose:Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models.Patients and Methods:We conducted a pilot study to evaluate the safety and preliminary …
View article: Supplementary Table 1 from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Supplementary Table 1 from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy Open
Representativeness of Study Participants
View article: Supplementary Table 1 from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Supplementary Table 1 from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy Open
Representativeness of Study Participants
View article: Data from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Data from A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy Open
Purpose:Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models.Patients and Methods:We conducted a pilot study to evaluate the safety and preliminary …
View article: 636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials Open
Background Chimeric antigen receptor (CAR) T-cell therapy has been challenging in solid tumors due to an absence of tumor-specific targets and the resultant on-target, off-tumor toxicity. Tmod, a novel logic-gated CAR T-cell therapy, utili…
View article: 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH) Open
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical efficacy in hematologic malignancies1; however, implementation of these therapies in solid tumors has been challenging due to a lack of tumor-sp…
View article: A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy Open
Purpose: Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models. Patients and Methods: We conducted a pilot study to evaluate the safety and prelimina…
View article: Supplementary Figures 1-4 from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Supplementary Figures 1-4 from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models Open
Supplementary Figure 1. Ulixertinib potentiates gemcitabine effect and this combination is well tolerated in mice; Supplementary Figure 2. Pharmacologic ERK inhibition increases p-MEK, ERK and AKT; Supplementary Figure 3. Ulixertinib syner…
View article: Supplementary Figures 1-4 from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Supplementary Figures 1-4 from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models Open
Supplementary Figure 1. Ulixertinib potentiates gemcitabine effect and this combination is well tolerated in mice; Supplementary Figure 2. Pharmacologic ERK inhibition increases p-MEK, ERK and AKT; Supplementary Figure 3. Ulixertinib syner…
View article: Data from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Data from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models Open
Effective treatment for pancreatic ductal adenocarcinoma (PDAC) is an urgent, unmet medical need. Targeting KRAS, the oncogene that is present in >95% of PDAC, is a heavily pursued strategy, but remains unsuccessful in the clinic. T…
View article: Data from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Data from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models Open
Effective treatment for pancreatic ductal adenocarcinoma (PDAC) is an urgent, unmet medical need. Targeting KRAS, the oncogene that is present in >95% of PDAC, is a heavily pursued strategy, but remains unsuccessful in the clinic. T…
View article: Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology Open
Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology,…
View article: Supplementary Methods, Figures 1-7 from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
Supplementary Methods, Figures 1-7 from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα Open
Supplementary Methods, Figures 1-7 from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
View article: Data from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
Data from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα Open
Cells deficient in the recQ-like helicase BLM are characterized by chromosome changes that suggest the disruption of normal mechanisms needed to resolve recombination intermediates and to maintain chromosome stability. Human BLM and topois…
View article: Supplementary Methods, Figures 1-7 from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
Supplementary Methods, Figures 1-7 from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα Open
Supplementary Methods, Figures 1-7 from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
View article: Data from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
Data from Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα Open
Cells deficient in the recQ-like helicase BLM are characterized by chromosome changes that suggest the disruption of normal mechanisms needed to resolve recombination intermediates and to maintain chromosome stability. Human BLM and topois…
View article: Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma Open
Background Ulixertinib is a novel oral ERK inhibitor that has shown promising single-agent activity in a phase I clinical trial that included patients with RAS-mutant cancers. Methods We conducted a phase Ib trial combining ulixertinib wit…
View article: IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma
IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma Open
View article: Aggregate Risk of Major Adverse Events in Patients Undergoing Neoadjuvant Chemotherapy and Surgical Resection for Pancreatic Adenocarcinoma
Aggregate Risk of Major Adverse Events in Patients Undergoing Neoadjuvant Chemotherapy and Surgical Resection for Pancreatic Adenocarcinoma Open